Dashboard
Manage Tickers

LLYELI LILLY & Co

NYSE lilly.com


$ 836.81 $ 5.05 (0.61 %)    

Thursday, 06-Jun-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.32 $ -0.36 (-0.08 %)
DIA $ 389.27 $ 0.80 (0.21 %)
SPY $ 534.63 $ -0.04 (-0.01 %)
TLT $ 93.23 $ -0.12 (-0.13 %)
GLD $ 219.44 $ 1.61 (0.74 %)
$ 837.29
$ 835.66
$ 0.00 x 0
$ 0.00 x 0
$ 834.21 - $ 846.49
$ 429.13 - $ 838.45
2,169,003
na
751.74B
$ 0.57
$ 122.47
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

eli-lillys-alzheimers-drug-donanemab-faces-fdas-adcomm-vote-next-week-on-data-risk-profile
Eli Lilly's Alzheimer's Drug, Donanemab Fa...
06/06/2024 16:07:42

The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10....

market-whales-and-their-recent-bets-on-lly-options
Market Whales and Their Recent Bets on LLY...
06/06/2024 15:30:52

us-fda-advisory-panel-to-vote-on-whether-available-data-show-that-lillys-donanemab-is-effective-for-treating-alzheimers-disease-in-patients-with-mild-cognitive-impairment--mild-dementia
U.S. FDA Advisory Panel To Vote On Whether...
06/06/2024 13:24:38

- Reuters

fda-staff-reviewers-report-higher-number-of-deaths-in-donanemab-treated-participants-compared-to-placebo-deaths-not-fully-explained-by-aria-or-cerebral-hemorrhage
FDA Staff Reviewers Report Higher Number O...
06/06/2024 12:56:24

- Reuters

chinese-generic-ozempic-wegovy-versions-could-put-novo-nordisk-at-the-risk-of-stiff-competition-in-key-market
Chinese Generic Ozempic, Wegovy Versions C...
06/06/2024 01:07:28

whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday
What's Going On With Fattly Liver Disease ...
06/05/2024 19:17:50

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

british-agency-supports-eli-lillys-weight-loss-drug-mounjaro-diverging-from-restrictions-on-rival-novo-nordisks-wegovy
British Agency Supports Eli Lilly's Weight...
06/05/2024 16:21:48

NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new av...

google-parent-alphabet-appoints-eli-lillys-finance-chief-ashkenazi-as-cfo
Google Parent Alphabet Appoints Eli Lilly'...
06/05/2024 14:11:49

Anat Ashkenazi resigns as CFO of Eli Lilly to join Google as CFO and SVP. She will remain at Lilly until July 2024 while her su...

eli-lilly-and-company-announced-that-anat-ashkenazi-has-resigned-as-chief-financial-officer-to-pursue-a-career-opportunity-outside-of-the-pharmaceutical-industry
Eli Lilly And Company Announced That Anat ...
06/05/2024 11:50:04

if-you-invested-100-in-this-stock-5-years-ago-you-would-have-700-today
If You Invested $100 In This Stock 5 Years...
06/04/2024 17:00:16

Core News & Articles
FDA Reports Limited Availability Of Mounja...
06/04/2024 13:11:14

- Reuters

structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforglipron-analyst-says
Structure Therapeutics Obesity Candidate I...
06/03/2024 19:14:17

Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Canto...

eli-lilly-beefs-up-neuro-pipeline-with-addition-of-preclinical-als-dementia-prospect
Eli Lilly Beefs Up Neuro Pipeline With Add...
06/03/2024 18:05:45

QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other n...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
06/03/2024 17:35:22

quralis-grants-lilly-exclusive-global-license-for-qrl-204-a-precision-therapy-that-restores-unc13a-function-in-als-and-ftd-for-an-upfront-payment-of-45m-plus-an-additional-equity-investment-quralis-is-also-eligible-for-future-milestone-payments-of-up-to-577m-and-tiered-royalties-on-net-sales
QurAlis Grants Lilly Exclusive Global Lice...
06/03/2024 16:35:52

QRL-204 is a splice-switching ASO generated through QurAlis' FlexASO™ Platform; represents Lilly's first program target...

eli-lilly-and-cos-options-a-look-at-what-the-big-money-is-thinking
Eli Lilly and Co's Options: A Look at What...
06/03/2024 14:01:04

reported-saturday-eli-lillys-olomorasib-presented-updated-data-from-the-phase-12-study-for-kras-g12c-mutant-solid-tumors-at-asco-2024
Reported Saturday, Eli Lilly's Olomorasib ...
06/03/2024 08:21:06

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non...

novo-nordisk-sues-additional-us-clinics-against-fake-semaglutide-products-used-for-weight-loss-diabetes
Novo Nordisk Sues Additional US Clinics Ag...
05/31/2024 18:08:28

Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure ...

performance-comparison-eli-lilly-and-co-and-competitors-in-pharmaceuticals-industry
Performance Comparison: Eli Lilly and Co A...
05/31/2024 15:00:14

new-weight-loss-etf-is-essentially-a-play-on-eli-lilly-novo-nordisk
New Weight Loss ETF Is Essentially A Play ...
05/30/2024 19:36:43

New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, w...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION